Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
نویسندگان
چکیده
IntroductionIn 2018, durvalumab was approved by the U.S. Food and Drug Administration as consolidation immunotherapy for patients with stage III NSCLC after definitive chemoradiotherapy (CRT). However, whether benefits EGFR-mutated remains unknown.MethodsWe conducted a multi-institutional retrospective analysis of unresectable who completed concurrent CRT. Kaplan-Meier analyses evaluated progression-free survival (PFS) between CRT or without durvalumab.ResultsAmong 37 patients, 13 initiated median 20 days completion. Two 12 months treatment, five discontinuing owing to progression immune-related adverse events (irAEs). Of 24 durvalumab, 16 alone eight induction EGFR tyrosine kinase inhibitors (TKIs). Median PFS 10.3 in received versus 6.9 (log-rank p = 0.993). TKI associated significantly longer (26.1 mo) compared 0.023). Six treated TKIs recurrence, one developing grade 4 pneumonitis on osimertinib.ConclusionsIn this study, did not benefit experienced high frequency irAEs. Patients initiate osimertinib may be susceptible incident Consolidation should approached caution setting further investigated treatment.
منابع مشابه
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
BACKGROUND Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progressi...
متن کاملGefitinib Treatment in EGFR Mutated Caucasian NSCLC
INTRODUCTION In the phase IV, open-label, single-arm study NCT01203917, first-line gefitinib 250 mg/d was effective and well tolerated in Caucasian patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (previously published). Here, we report EGFR mutation analyses of plasma-derived, circulating-free tumor DNA. METHODS Mandatory tumor and duplicate ...
متن کاملBeyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients
PURPOSE Treatment and clinical-outcomes were described in a sub-cohort of non-small-cell lung cancer (NSCLC) patients with disease-progression (PD) after epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) treatment. PATIENTS AND METHODS We retrospectively analyzed a single-institutional EGFR mutation positive (EGFRmut+) NSCLC cohort for post-TKI-PD management, and assessed overall...
متن کاملDefinitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer
PURPOSE The purpose of this study is to compare the treatment outcomes for locally advanced resectable hypopharyngeal cancer between organ-preserving chemoradiotherapy (CRT) and surgery followed by radiotherapy (SRT). MATERIALS AND METHODS We reviewed 91 patients with stage III/IV hypopharyngeal squamous cell carcinoma treated with radiotherapy (RT). In the CRT group (n=34), 18 patients were ...
متن کاملOutcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
Background Several mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated NSCLC have been described including the T790M mutation and MET amplification. Whereas T790M mutation confers prolonged survival and sensitivity to 3rd generation TKIs, data are lacking on clinical features and outcome of MET-driven resistant EGFR-mutated NSCLC patients. Methods Patie...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2021
ISSN: ['1556-0864', '1556-1380']
DOI: https://doi.org/10.1016/j.jtho.2021.01.1628